The CEO of Covance has warned it will be “very, very difficult” for CROs expanding through M&A to integrate assets, and the process could see clients go elsewhere.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Cetero, Harlan, Numerate and Idea Pharma.
The contract service market failed to recover as hoped in 2010 and consequently many companies made cutbacks. Outsourcing-Pharma rounds up five of the most read of 2010.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at PharmaNet, PPD, BASi and WorldCare Clinical.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at Ricerca Biosciences, Trialytics, CeeTox and Firecrest Clinical.
Outsourcing-Pharma presents its latest round up of movements in the pharma outsourcing sector, including appointments at DPT, PPD, Catalent and INC Research.
MDS Pharma Services’ Central Labs division is to be acquired by Czura Thornton, a private investment group that owns Chiltern, for approximately $8m (€5.4m) as part of the CRO’s repositioning.
MDS Pharma Services has become the first CRO in the UK and second in the US to gain certification from the Brazilian regulatory agency after a “major client” requested it sought accreditation.
The outsourcing “market is poised to return to healthier growth rates in 2010”, according to the president of MDS Pharma Services who also told Outsourcing-Pharma that CROs will play an increasingly important role in drug development.
MDS Pharma Services posted an 18 per cent drop in revenue in its Q2 results, which also contained details of restructuring that will affect 180 people and cost $4m (€2.8m).
MDS Pharma Services is renovating and expanding its Taiwanese discovery pharmacology operation in response to growing global demand for work performed in Asia.
Canadian CRO MDS Pharma Services (MDS) is to sell its Phase II-IV trial business to US counterpart INC Research for $50m (€35m) and focus on providing discovery and early clinical development services.
The tough operating climate facing contract research organisations (CROs) seems to have hit Canada’s MDS particularly hard, with a 13 per cent drop in fiscal first quarter revenues to $257m.
MDS has formed a special committee to improve shareholder value following poor results and pressure from investors to sell some of its business units, which include a CRO division.
Beleaguered life science tools and services company MDS Inc, has recorded disappointing third quarter results, with revenues from its Analytical Technologies and MDS Pharma Services divisions missing forecasts.
Life science tools and services company MDS Inc has said it will cut about 210 jobs at two of its divisions - its MDS Pharma Services and MDS Analytical Technologies – in a bid to reduce costs by around $20m a year.
Contract research organisation MDS Pharma Services has launched a
new version of its ClinQuick electronic data capture (EDC) system
designed to help in the design and management of Phase I clinical
studies.
MDS Pharma Services has expanded its portfolio of bioanalytical
testing services with the addition of electrochemiluminescent assay
(ECLA) capability, used to test biological samples from clinical
research participants.
Outsourcing-Pharma.com compiles the news that has featured in the
clinical contract community of late, involving MDS Pharma Services,
Almac Clinical Technologies and Pharm-Olam International.
MDS Pharma Services is the latest contract research organisation
(CRO) to branch out into a new and exotic emerging market location,
with the establishment of an office in Sao Paulo, Brazil.
General Electric and MDS Pharma Services announced today the
availability of a new, automated in vitro micronucleus assay that
will form part of a broad panel of drug discovery safety
assessments offered by MDS Pharma Services pharmacology...
A deal has been finalised making MDS Pharma Services the preferred
contract research organization (CRO) of the Multiple Myeloma
Research Consortium (MMRC) in the US, with further opportunities in
Europe to follow.
